. 2017 Feb 10;37(5):503–509. doi: 10.1007/s40261-017-0499-y

Table 4.

Differences between subcutaneous injection regions for total exposure and maximum concentration of insulin lispro, insulin glulisine, insulin aspart and faster aspart

	Mean^a			Ratio (%)
	Abdomen	Upper arm	Thigh	Upper arm/abdomen	Thigh/abdomen
Total exposure (pmol·h/L)
Insulin lispro [5]	1388	1313	1277	95	92
Insulin glulisine [7]	2182	2119	2021	97	93
Insulin aspart [6]	1300	1361	1265	105	97
Faster aspart	1001^b	922^b	927^b	92	93
Maximum concentration (pmol/L)
Insulin lispro [5]	589	395	458	67	78
Insulin glulisine [7]	1003	821	684	82	68
Insulin aspart [6]	501	506	422	101	84
Faster aspart	395^b	364^b	276^b	92	70

All data are for a dose of 0.2 U/kg. Insulin glulisine data have been dose-adjusted from 0.1 U/kg assuming dose-proportionality

^aAbsolute levels of total exposure and maximum concentration should be compared with caution between the different insulin products, since results originate from different studies

^bAbsolute levels of total exposure and maximum concentration for faster aspart are not comparable to the other insulin products, since free (i.e. unbound), rather than total (i.e. bound plus unbound), insulin concentration was measured in the current study